Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7817611 | 0.89 | CHRM1 (0.52) | CHRM1CHRM2 | |
| SCHEMBL6790328 | 0.86 | CHRM1 (0.55) | CHRM1CHRM2 | |
| SCHEMBL7893299 | 0.84 | CHRM1 (0.53) | CHRM1CHRM2 | |
| SCHEMBL7810254 | 0.79 | CHRM1 (0.57) | CHRM1CHRM2 | |
| SCHEMBL8183480 | 0.77 | SLC6A4 (0.39) | CHRM1 | |
| SCHEMBL7810258 | 0.77 | CHRM1 (0.64) | CHRM1CHRM2 | |
| Hydrochloric Acid SCHEMBL8193630 | 0.76 | SLC6A4 (0.39) | CHRM1 | |
| SCHEMBL8068625 | 0.75 | CHRM1 (0.53) | CHRM1CHRM2 | |
| SCHEMBL7819633 | 0.74 | CHRM1 (0.62) | CHRM1CHRM2 | |
| SCHEMBL3218615 | 0.74 | CARM1 (0.49) | CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | claimed |
| US-6187798-B1 | (+-)EXO-3-(3-(4-CHLOROPHENYL)PROPYNYLOXY-4-(1 -AZABICYCLO(2.2.1)HEPTYL-3-OXY)-1,2,5-THIADIAZOLE, FOR EXAMPLE; FOR MODULATING A MUSCARINIC RECEPTOR; TREATING ALZHEIMER'S DISEASE OR PSYCHOSIS | ELI LILLY AND COMPANY | 2001-02-13 | — | — | US | claimed |
| US-6069159-A | USEFUL AS STIMULANTS OF THE COGNITIVE FUNCTION OF THE FOREBRAIN AND HIPPOCAMPUS OF MAMMALS | ELI LILLY AND COMPANY (US) | 2000-05-30 | — | — | US | claimed |
| US-6720342-B2 | AZABICYCLIC COMPOUNDS USED IN TREATING A DISEASE IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF THE MUSCARINIC CHOLINERGIC SYSTEM. | NOVO NORDISK A/S (DK) | 2004-04-13 | — | — | US | disclosed |
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| EP-0900217-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6069159-A | USEFUL AS STIMULANTS OF THE COGNITIVE FUNCTION OF THE FOREBRAIN AND HIPPOCAMPUS OF MAMMALS | ELI LILLY AND COMPANY (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0900217-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997040042-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | CHRM5, ACHE, CHRM2 | CHRM1 5/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.